

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KELUN-BIOTECH
科伦博泰

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

NOTICE OF BOARD MEETING

The board of directors (the “**Board**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board will be held on Monday, 18 August 2025 for the purpose of, among other matters, considering and approving the interim results of the Company and its subsidiaries for the six months ended 30 June 2025 and its release, and transacting other business.

Following the release of the interim results, the Company will host a conference call with the Company’s management at 8:00 p.m. Hong Kong/Beijing Time on Monday, 18 August, 2025 (12:00 noon GMT/8:00 a.m. U.S. Eastern Time on Monday, 18 August, 2025).

The conference call will be webcast live and a link to the webcast can be accessed from the investor relations section of the Company’s website at <https://en.kelun-biotech.com/news.aspx?mid=159>. To ensure a timely connection, it is recommended that participants register at least 30 minutes prior to the scheduled webcast.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, 6 August 2025

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.